Sanuwave Health reports preliminary Q2 revenue $9.6-$9.8M, above guidance but down 3-5% YoY

SANUWAVE Health, Inc.

Preliminary Q2 2026 revenue of $9.6M-$9.8M, above revised guidance of $8.5M-$9.5M but down ~3-5% from $10.1M in Q2 2025.
Consumable applicator sales set all-time records for both unit sales and revenue, indicating growing Ultramist adoption.
Capital sales faced headwinds from customer stress and used Ultramist systems; trade-in program for certified pre-owned units showing success.
Results are preliminary and subject to adjustment upon completion of quarter-end close and review procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.